dasatinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
tyrosine kinase inhibitors	785	302962-49-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dasatinib sprycel spyrcel BMS-354825 dasatinib hydrate	A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB. Molecular weight: 488.01 Formula: C22H26ClN7O2S CLOGP: 2.71 LIPINSKI: 0 HAC: 9 HDO: 3 TPSA: 106.51 ALOGS: -4.58 ROTB: 7 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

dasatinib
sprycel
spyrcel
BMS-354825
dasatinib hydrate

A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.

Molecular weight: 488.01
Formula: C22H26ClN7O2S
CLOGP: 2.71
LIPINSKI: 0
HAC: 9
HDO: 3
TPSA: 106.51
ALOGS: -4.58
ROTB: 7

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	5.85 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	15 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Nov. 20, 2006	EMA	BRISTOL-MYERS SQUIBB PHARMA EEIG
June 28, 2006	FDA	BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pleural effusion	1431.28	18.52	667	20102	92543	63375710
Cytogenetic analysis abnormal	339.31	18.52	75	20694	845	63467408
Adverse event	322.54	18.52	226	20543	67333	63400920
Drug resistance	316.35	18.52	153	20616	22780	63445473
Hospitalisation	257.35	18.52	217	20552	84864	63383389
Philadelphia chromosome positive	252.68	18.52	51	20718	355	63467898
Pulmonary oedema	246.63	18.52	177	20592	54696	63413557
Prescribed underdose	243.68	18.52	140	20629	29549	63438704
Malignant neoplasm progression	215.11	18.52	193	20576	81928	63386325
Acute lymphocytic leukaemia recurrent	213.20	18.52	62	20707	2207	63466046
Pericardial effusion	175.45	18.52	114	20655	29944	63438309
Fluid retention	163.63	18.52	144	20625	59542	63408711
Exposure via body fluid	156.11	18.52	37	20732	579	63467674
Nausea	146.64	18.52	608	20161	853863	62614390
Chylothorax	142.20	18.52	30	20739	266	63467987
Diarrhoea	139.43	18.52	530	20239	714836	62753417
Blast crisis in myelogenous leukaemia	133.59	18.52	32	20737	525	63467728
Death	132.86	18.52	342	20427	374039	63094214
Headache	115.69	18.52	460	20309	632781	62835472
Rash	111.83	18.52	419	20350	560452	62907801
Fatigue	99.16	18.52	559	20210	887469	62580784
Bone pain	93.69	18.52	102	20667	54539	63413714
Chronic myeloid leukaemia transformation	85.16	18.52	17	20752	111	63468142
Thrombocytopenia	82.39	18.52	164	20605	150993	63317260
Chronic myeloid leukaemia recurrent	79.99	18.52	18	20751	221	63468032
Blast cell crisis	72.49	18.52	14	20755	75	63468178
Pancytopenia	66.33	18.52	116	20653	96817	63371436
Infusion related reaction	64.46	18.52	4	20765	245517	63222736
Enterocolitis haemorrhagic	62.66	18.52	22	20747	1444	63466809
Acne	59.42	18.52	54	20715	23239	63445014
Pulmonary hypertension	56.25	18.52	65	20704	37058	63431195
Large granular lymphocytosis	55.99	18.52	13	20756	185	63468068
Leukaemia recurrent	53.09	18.52	19	20750	1319	63466934
Chronic myeloid leukaemia	52.86	18.52	22	20747	2296	63465957
Cytopenia	51.08	18.52	37	20732	11564	63456689
Haematotoxicity	50.88	18.52	34	20735	9342	63458911
Fall	49.40	18.52	34	20735	392300	63075953
Therapeutic product effect decreased	48.24	18.52	4	20765	193183	63275070
Pulmonary arterial hypertension	47.40	18.52	47	20722	22530	63445723
Platelet count decreased	47.22	18.52	112	20657	116010	63352243
Product dose omission issue	47.19	18.52	176	20593	234137	63234116
Bone marrow transplant	47.11	18.52	15	20754	727	63467526
Arthropathy	46.53	18.52	10	20759	234782	63233471
Myalgia	45.81	18.52	128	20641	146401	63321852
Condition aggravated	45.36	18.52	39	20730	402178	63066075
Acute graft versus host disease	44.84	18.52	24	20745	4404	63463849
Anaemia	44.56	18.52	202	20567	293228	63175025
Therapeutic response delayed	44.55	18.52	14	20755	650	63467603
Polymerase chain reaction positive	43.03	18.52	10	20759	143	63468110
Lymphoid tissue hyperplasia	40.41	18.52	10	20759	189	63468064
Exposure during pregnancy	39.45	18.52	3	20766	155544	63312709
Joint swelling	37.87	18.52	31	20738	327635	63140618
Aspiration pleural cavity	37.01	18.52	13	20756	854	63467399
Strongyloidiasis	35.90	18.52	14	20755	1234	63467019
Neutropenia	34.82	18.52	131	20638	174874	63293379
Nephrotic syndrome	34.61	18.52	22	20747	5554	63462699
Dyspnoea	34.19	18.52	348	20421	660965	62807288
Drug hypersensitivity	33.95	18.52	31	20738	310656	63157597
Enterococcal bacteraemia	33.78	18.52	14	20755	1445	63466808
Gene mutation identification test positive	33.24	18.52	8	20761	134	63468119
Emergency care examination	32.24	18.52	7	20762	72	63468181
Stem cell transplant	30.79	18.52	14	20755	1808	63466445
Graft versus host disease	30.76	18.52	22	20747	6741	63461512
Discomfort	29.55	18.52	9	20760	167365	63300888
Philadelphia positive chronic myeloid leukaemia	29.45	18.52	6	20763	44	63468209
Chronic graft versus host disease	29.15	18.52	16	20753	3086	63465167
Hepatitis chronic active	28.06	18.52	6	20763	57	63468196
Generalised oedema	27.91	18.52	30	20739	15788	63452465
Musculoskeletal stiffness	27.48	18.52	13	20756	184605	63283648
Therapy cessation	26.99	18.52	41	20728	30416	63437837
Pleurisy	26.66	18.52	22	20747	8318	63459935
Systemic candida	25.79	18.52	15	20754	3230	63465023
Alopecia	24.80	18.52	192	20577	337344	63130909
Acquired gene mutation	24.70	18.52	10	20759	973	63467280
Normal newborn	24.59	18.52	21	20748	8320	63459933
Colitis	23.27	18.52	50	20719	48478	63419775
Subdural haematoma	23.24	18.52	26	20743	14302	63453951
Tessellated fundus	23.16	18.52	5	20764	50	63468203
Full blood count decreased	23.01	18.52	35	20734	25989	63442264
Gene mutation	22.61	18.52	11	20758	1654	63466599
Periorbital oedema	22.49	18.52	17	20752	5667	63462586
Skin disorder	22.39	18.52	37	20732	29470	63438783
Cytomegalovirus colitis	21.64	18.52	12	20757	2360	63465893
Pericarditis	21.61	18.52	8	20761	131571	63336682
C-reactive protein increased	21.00	18.52	3	20766	94704	63373549
Cytomegalovirus enterocolitis	20.87	18.52	8	20761	673	63467580
Skin toxicity	20.67	18.52	15	20754	4699	63463554
Febrile neutropenia	20.57	18.52	85	20684	118364	63349889
Psoriatic arthropathy	20.06	18.52	3	20766	91517	63376736
Lymphocytosis	19.92	18.52	12	20757	2755	63465498
Leukaemia	19.85	18.52	14	20755	4194	63464059
Demyelinating polyneuropathy	19.80	18.52	8	20761	774	63467479
Vomiting	19.77	18.52	274	20495	559343	62908910
Intentional product use issue	19.32	18.52	88	20681	127804	63340449
Impaired healing	19.05	18.52	5	20764	102537	63365716
Blast cell proliferation	19.00	18.52	3	20766	3	63468250

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pleural effusion	1811.75	15.62	897	19289	80649	34856096
Adverse event	471.22	15.62	226	19960	18651	34918094
Drug resistance	442.11	15.62	240	19946	25687	34911058
Philadelphia chromosome positive	346.23	15.62	72	20114	304	34936441
Prescribed underdose	272.61	15.62	123	20063	8810	34927935
Hospitalisation	259.24	15.62	234	19952	56668	34880077
Malignant neoplasm progression	248.13	15.62	279	19907	87767	34848978
Cytogenetic analysis abnormal	247.20	15.62	62	20124	677	34936068
Chylothorax	229.09	15.62	59	20127	722	34936023
Drug intolerance	208.72	15.62	212	19974	59358	34877387
Blast crisis in myelogenous leukaemia	183.87	15.62	47	20139	557	34936188
Headache	153.06	15.62	349	19837	200286	34736459
Fluid retention	145.31	15.62	122	20064	26765	34909980
Pulmonary oedema	144.68	15.62	157	20029	47372	34889373
Acute lymphocytic leukaemia recurrent	143.14	15.62	57	20129	2987	34933758
Pericardial effusion	139.71	15.62	115	20071	24547	34912198
Fatigue	125.96	15.62	483	19703	370170	34566575
Death	88.22	15.62	457	19729	397592	34539153
Gene mutation	86.36	15.62	32	20154	1376	34935369
Large granular lymphocytosis	80.96	15.62	20	20166	204	34936541
Rash	80.87	15.62	297	19889	222455	34714290
Pulmonary hypertension	72.29	15.62	74	20112	20850	34915895
Acne	69.84	15.62	55	20131	11011	34925734
Acquired gene mutation	69.41	15.62	27	20159	1328	34935417
Diarrhoea	63.59	15.62	413	19773	389499	34547246
Chronic myeloid leukaemia transformation	56.22	15.62	14	20172	148	34936597
Bone pain	52.11	15.62	62	20124	20624	34916121
Hypotension	51.86	15.62	32	20154	221617	34715128
Thrombocytopenia	51.34	15.62	202	19984	156045	34780700
Chronic myeloid leukaemia	50.52	15.62	25	20161	2199	34934546
Pulmonary arterial hypertension	49.97	15.62	41	20145	8698	34928047
Loss of therapeutic response	49.15	15.62	17	20169	597	34936148
Philadelphia positive chronic myeloid leukaemia	48.70	15.62	12	20174	121	34936624
Blast cell proliferation	47.19	15.62	8	20178	6	34936739
Lymphoid tissue hyperplasia	44.47	15.62	10	20176	65	34936680
Aspiration pleural cavity	43.88	15.62	17	20169	827	34935918
Bone marrow transplant	40.01	15.62	17	20169	1051	34935694
Intentional product use issue	39.89	15.62	99	20087	59717	34877028
Chronic myeloid leukaemia recurrent	39.02	15.62	11	20175	193	34936552
Minimal residual disease	38.50	15.62	13	20173	424	34936321
Central nervous system neoplasm	37.54	15.62	9	20177	80	34936665
Gene mutation identification test positive	37.06	15.62	10	20176	148	34936597
Leukaemia recurrent	36.22	15.62	18	20168	1597	34935148
Pleurisy	35.38	15.62	26	20160	4695	34932050
Cytopenia	35.16	15.62	40	20146	12683	34924062
Therapy cessation	34.96	15.62	46	20140	16927	34919818
Condition aggravated	34.59	15.62	36	20150	192160	34744585
Oedema	34.03	15.62	79	20107	45662	34891083
Loss of CAR T-cell persistence	33.95	15.62	7	20179	28	34936717
Treatment failure	31.88	15.62	78	20108	46619	34890126
Myopathy toxic	31.16	15.62	12	20174	574	34936171
Bradycardia	30.04	15.62	4	20182	75414	34861331
Natural killer cell count increased	29.94	15.62	5	20181	3	34936742
Fall	28.28	15.62	46	20140	202839	34733906
Enterocolitis haemorrhagic	28.28	15.62	13	20173	970	34935775
Therapy change	27.81	15.62	19	20167	3058	34933687
Bone marrow disorder	26.60	15.62	15	20171	1720	34935025
Nausea	26.46	15.62	306	19880	339602	34597143
Blast cell crisis	26.44	15.62	7	20179	96	34936649
Drug clearance decreased	25.95	15.62	15	20171	1803	34934942
Chronic myeloid leukaemia (in remission)	25.83	15.62	4	20182	0	34936745
Second primary malignancy	25.62	15.62	27	20159	7859	34928886
Toxicity to various agents	25.58	15.62	48	20138	200314	34736431
Neoplasm recurrence	25.48	15.62	16	20170	2233	34934512
Anterior interosseous syndrome	25.37	15.62	5	20181	15	34936730
Clonal evolution	24.72	15.62	7	20179	125	34936620
Platelet count decreased	24.59	15.62	135	20051	119582	34817163
Hyperplasia	23.91	15.62	10	20176	594	34936151
Therapeutic response decreased	23.32	15.62	52	20134	29261	34907484
Right ventricular dysfunction	23.15	15.62	12	20174	1164	34935581
Chromosome analysis abnormal	23.01	15.62	7	20179	162	34936583
Skin disorder	22.33	15.62	33	20153	13522	34923223
Graft versus host disease	22.31	15.62	29	20157	10540	34926205
Product dose omission issue	21.96	15.62	131	20055	119580	34817165
Hepatotoxicity	21.65	15.62	42	20144	21443	34915302
Hyperkalaemia	20.88	15.62	7	20179	69382	34867363
Hyphaema	20.85	15.62	9	20177	578	34936167
Infusion related reaction	20.69	15.62	3	20183	53054	34883691
Acute kidney injury	20.24	15.62	99	20087	304889	34631856
Dyspnoea	20.13	15.62	317	19869	376465	34560280
Overdose	20.09	15.62	14	20172	91045	34845700
Cerebellar syndrome	19.83	15.62	14	20172	2374	34934371
Gelatinous transformation of the bone marrow	19.82	15.62	4	20182	14	34936731
Drug hypersensitivity	19.68	15.62	11	20175	80518	34856227
Bone neoplasm	19.47	15.62	7	20179	276	34936469
Myalgia	19.42	15.62	98	20088	84012	34852733
Central nervous system leukaemia	19.39	15.62	7	20179	279	34936466
Syncope	18.97	15.62	15	20171	91436	34845309
Peripheral arterial occlusive disease	18.89	15.62	20	20166	5854	34930891
Pancytopenia	18.66	15.62	106	20080	95051	34841694
Rectosigmoid cancer	18.41	15.62	6	20180	175	34936570
Subdural hygroma	18.02	15.62	7	20179	343	34936402
Loss of consciousness	17.86	15.62	13	20173	82654	34854091
Myeloproliferative neoplasm	17.75	15.62	8	20178	570	34936175
Hallucination	17.73	15.62	4	20182	51494	34885251
Allogenic bone marrow transplantation therapy	17.66	15.62	4	20182	27	34936718
B-cell small lymphocytic lymphoma	17.62	15.62	6	20180	201	34936544
Cytomegalovirus infection reactivation	17.48	15.62	18	20168	5100	34931645
Peripheral artery stenosis	17.46	15.62	9	20177	863	34935882
Cardiac arrest	17.29	15.62	18	20168	96141	34840604
Rhabdomyolysis	17.10	15.62	9	20177	68154	34868591
Oxygen saturation decreased	16.96	15.62	5	20181	53813	34882932
Coma	16.87	15.62	3	20183	45675	34891070
Tremor	16.56	15.62	14	20172	82573	34854172
Confusional state	16.30	15.62	37	20149	144123	34792622
Acute lymphocytic leukaemia refractory	16.26	15.62	5	20181	120	34936625
Bone development abnormal	16	15.62	4	20182	43	34936702
Eye swelling	15.98	15.62	24	20162	9971	34926774
Haemothorax	15.86	15.62	15	20171	3837	34932908
Deep vein thrombosis	15.81	15.62	9	20177	65239	34871506
Eyelid oedema	15.69	15.62	17	20169	5107	34931638
Subclavian artery stenosis	15.68	15.62	4	20182	47	34936698
Polymerase chain reaction positive	15.67	15.62	5	20181	136	34936609
Therapy non-responder	15.65	15.62	54	20132	39092	34897653

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pleural effusion	2698.34	15.38	1250	29825	144012	79569301
Drug resistance	531.23	15.38	280	30795	41933	79671380
Philadelphia chromosome positive	462.81	15.38	95	30980	595	79712718
Chylothorax	411.80	15.38	88	30987	687	79712626
Malignant neoplasm progression	357.57	15.38	346	30729	135644	79577669
Cytogenetic analysis abnormal	322.32	15.38	78	30997	1112	79712201
Pulmonary oedema	289.05	15.38	254	30821	88000	79625313
Pericardial effusion	283.18	15.38	193	30882	46044	79667269
Hospitalisation	272.77	15.38	253	30822	93983	79619330
Prescribed underdose	262.59	15.38	156	30919	29358	79683955
Adverse event	254.69	15.38	201	30874	60013	79653300
Blast crisis in myelogenous leukaemia	240.44	15.38	58	31017	815	79712498
Fluid retention	216.74	15.38	195	30880	69614	79643699
Acute lymphocytic leukaemia recurrent	208.69	15.38	76	30999	4648	79708665
Death	182.97	15.38	559	30516	565955	79147358
Headache	159.52	15.38	587	30488	653185	79060128
Rash	147.51	15.38	527	30548	577831	79135482
Large granular lymphocytosis	145.32	15.38	33	31042	350	79712963
Fatigue	141.68	15.38	724	30351	929003	78784310
Diarrhoea	134.31	15.38	686	30389	879803	78833510
Chronic myeloid leukaemia transformation	129.20	15.38	28	31047	235	79713078
Thrombocytopenia	120.44	15.38	297	30778	264962	79448351
Acne	106.87	15.38	87	30988	27103	79686210
Enterocolitis haemorrhagic	95.80	15.38	35	31040	2159	79711154
Gene mutation	92.43	15.38	36	31039	2650	79710663
Acquired gene mutation	91.51	15.38	34	31041	2199	79711114
Pulmonary arterial hypertension	91.46	15.38	81	30994	28285	79685028
Chronic myeloid leukaemia	84.88	15.38	37	31038	3627	79709686
Pulmonary hypertension	84.64	15.38	99	30976	47981	79665332
Bone pain	83.86	15.38	106	30969	55636	79657677
Philadelphia positive chronic myeloid leukaemia	76.51	15.38	17	31058	162	79713151
Nausea	74.29	15.38	630	30445	956566	78756747
Infusion related reaction	67.60	15.38	6	31069	230231	79483082
Fall	65.89	15.38	56	31019	487573	79225740
Condition aggravated	63.59	15.38	61	31014	501063	79212250
Platelet count decreased	62.37	15.38	192	30883	194472	79518841
Therapy cessation	62.24	15.38	75	31000	37487	79675826
Pancytopenia	62.23	15.38	173	30902	165572	79547741
Aspiration pleural cavity	60.38	15.38	23	31052	1594	79711719
Pleurisy	57.69	15.38	41	31034	10434	79702879
Blast cell crisis	56.98	15.38	13	31062	141	79713172
Bone marrow transplant	55.52	15.38	21	31054	1427	79711886
Leukaemia recurrent	51.49	15.38	24	31051	2750	79710563
Blast cell proliferation	50.33	15.38	8	31067	6	79713307
Cytopenia	49.96	15.38	50	31025	20333	79692980
Therapy change	47.92	15.38	32	31043	7367	79705946
Hypotension	47.70	15.38	61	31014	440256	79273057
Therapeutic product effect decreased	46.18	15.38	5	31070	163858	79549455
Febrile neutropenia	45.16	15.38	194	30881	230805	79482508
Arthropathy	43.84	15.38	8	31067	177103	79536210
Drug intolerance	42.15	15.38	209	30866	263910	79449403
Drug hypersensitivity	41.97	15.38	33	31042	298883	79414430
Full blood count decreased	41.92	15.38	52	31023	26767	79686546
Natural killer cell count increased	40.97	15.38	7	31068	12	79713301
Oedema	40.20	15.38	120	30955	119460	79593853
Lymphoid tissue hyperplasia	40.05	15.38	11	31064	264	79713049
Haematotoxicity	39.76	15.38	39	31036	15480	79697833
Musculoskeletal stiffness	39.05	15.38	10	31065	174998	79538315
Graft versus host disease	38.94	15.38	38	31037	14988	79698325
Chronic myeloid leukaemia recurrent	38.93	15.38	11	31064	294	79713019
Drug clearance decreased	38.79	15.38	21	31054	3306	79710007
Polymerase chain reaction positive	37.91	15.38	11	31064	324	79712989
Clonal evolution	37.15	15.38	10	31065	222	79713091
Cytomegalovirus colitis	37.11	15.38	23	31052	4662	79708651
Colitis	36.30	15.38	85	30990	73222	79640091
Chromosome analysis abnormal	36.29	15.38	10	31065	243	79713070
Lower respiratory tract infection	36.26	15.38	4	31071	129216	79584097
Gene mutation identification test positive	35.99	15.38	10	31065	251	79713062
Chronic myeloid leukaemia (in remission)	35.22	15.38	6	31069	10	79713303
Therapeutic response delayed	34.73	15.38	14	31061	1128	79712185
Toxicity to various agents	33.85	15.38	71	31004	421469	79291844
Mobility decreased	33.73	15.38	4	31071	122171	79591142
Mucosal inflammation	33.54	15.38	84	30991	75496	79637817
Central nervous system neoplasm	33.32	15.38	8	31067	110	79713203
Anaemia	32.75	15.38	290	30785	444725	79268588
Generalised oedema	32.38	15.38	43	31032	23666	79689647
Nephrotic syndrome	32.27	15.38	30	31045	11144	79702169
Enterococcal bacteraemia	32.01	15.38	18	31057	3050	79710263
Loss of CAR T-cell persistence	31.46	15.38	6	31069	24	79713289
Myalgia	31.10	15.38	149	30926	185492	79527821
Neutropenia	30.36	15.38	204	30871	287506	79425807
Skin disorder	29.74	15.38	50	31025	33893	79679420
Systemic candida	29.64	15.38	23	31052	6683	79706630
Glossodynia	29.50	15.38	3	31072	103334	79609979
Minimal residual disease	29.44	15.38	10	31065	497	79712816
Exposure during pregnancy	28.71	15.38	3	31072	101129	79612184
Intentional product use issue	28.36	15.38	126	30949	151986	79561327
Bone marrow failure	28.35	15.38	62	31013	51045	79662268
Joint swelling	28.21	15.38	43	31032	288603	79424710
Somnolence	28.09	15.38	31	31044	238950	79474363
Dyspnoea	28.07	15.38	479	30596	856546	78856767
Strongyloidiasis	28.03	15.38	18	31057	3880	79709433
Bone marrow disorder	27.98	15.38	17	31058	3326	79709987
Intentional overdose	27.98	15.38	4	31071	105956	79607357
Primary effusion lymphoma	27.83	15.38	6	31069	49	79713264
Oxygen saturation decreased	27.61	15.38	8	31067	129039	79584274
Emergency care examination	27.61	15.38	7	31068	122	79713191
Central nervous system leukaemia	27.10	15.38	9	31066	417	79712896
Periorbital oedema	27.09	15.38	24	31051	8378	79704935
Overdose	26.27	15.38	20	31055	184186	79529127
Anterior interosseous syndrome	25.65	15.38	5	31070	23	79713290
Skin toxicity	25.33	15.38	23	31052	8291	79705022
Acute graft versus host disease	25.02	15.38	25	31050	10142	79703171
Growth retardation	24.72	15.38	13	31062	1930	79711383
White blood cell count decreased	24.55	15.38	141	30934	188147	79525166
Therapeutic response decreased	24.29	15.38	69	31006	66784	79646529
C-reactive protein increased	24.16	15.38	10	31065	129017	79584296
Loss of therapeutic response	24.03	15.38	10	31065	874	79712439
Stem cell transplant	23.94	15.38	16	31059	3688	79709625
Hyperplasia	23.84	15.38	11	31064	1232	79712081
Cytomegalovirus enterocolitis	23.73	15.38	12	31063	1643	79711670
Syncope	23.71	15.38	21	31054	179428	79533885
Peripheral artery stenosis	23.28	15.38	11	31064	1300	79712013
Transplant	22.77	15.38	10	31065	998	79712315
Lymphocytosis	22.74	15.38	17	31058	4676	79708637
Second primary malignancy	22.71	15.38	28	31047	14322	79698991
Haemothorax	22.52	15.38	18	31057	5460	79707853
Cytomegalovirus infection reactivation	22.51	15.38	22	31053	8694	79704619
Multiple-drug resistance	22.31	15.38	22	31053	8786	79704527
Tessellated fundus	22.28	15.38	5	31070	50	79713263
Metabolic acidosis	22.06	15.38	3	31072	82526	79630787
Myopathy toxic	21.95	15.38	10	31065	1088	79712225
Bradycardia	21.62	15.38	13	31062	135544	79577769
Peripheral arterial occlusive disease	21.61	15.38	21	31054	8237	79705076
Discomfort	21.55	15.38	11	31064	125606	79587707
Splenomegaly	21.50	15.38	33	31042	20721	79692592
Asthma	21.49	15.38	13	31062	135082	79578231
Osteoarthritis	21.47	15.38	4	31071	87305	79626008
Leukaemia	21.28	15.38	18	31057	5907	79707406
Hypersensitivity	21.17	15.38	44	31031	262195	79451118
Inappropriate schedule of product administration	21.06	15.38	13	31062	133615	79579698
Right ventricular dysfunction	21.03	15.38	13	31062	2622	79710691
Hyphaema	20.52	15.38	9	31066	895	79712418
Psoriatic arthropathy	20.46	15.38	3	31072	77996	79635317
Product administered to patient of inappropriate age	20.21	15.38	17	31058	5536	79707777
Psoriasis	20.21	15.38	5	31070	89582	79623731
Intentional product misuse	20.17	15.38	6	31069	95159	79618154
Hepatitis chronic active	19.85	15.38	6	31069	204	79713109
Malaise	19.81	15.38	111	30964	489758	79223555
Acute lymphocytic leukaemia	19.73	15.38	16	31059	4953	79708360
Subdural haematoma	19.60	15.38	40	31035	31394	79681919
Product dose omission issue	19.57	15.38	164	30911	247373	79465940
Blast cell count increased	19.57	15.38	10	31065	1400	79711913
Eye swelling	19.33	15.38	36	31039	26432	79686881
Blood pressure increased	19.22	15.38	33	31042	211327	79501986
Hydrothorax	19.19	15.38	10	31065	1458	79711855
Chronic graft versus host disease	19.18	15.38	18	31057	6763	79706550
Therapy non-responder	19.16	15.38	79	30996	92226	79621087
Confusional state	19.05	15.38	62	31013	317935	79395378
Tremor	18.97	15.38	23	31052	170060	79543253
Pyrexia	18.88	15.38	370	30705	678339	79034974
Hepatotoxicity	18.65	15.38	53	31022	51299	79662014
Coma	18.52	15.38	8	31067	100641	79612672
Loss of consciousness	18.42	15.38	23	31052	167920	79545393
Cerebellar syndrome	18.36	15.38	16	31059	5464	79707849
Cardiac failure	18.28	15.38	113	30962	154729	79558584
Subdural hygroma	18.15	15.38	7	31068	502	79712811
Alopecia	18.14	15.38	153	30922	231202	79482111
Allogenic bone marrow transplantation therapy	17.56	15.38	4	31071	43	79713270
Sinusitis	17.34	15.38	31	31044	195470	79517843
Bacteraemia	17.28	15.38	39	31036	32785	79680528
Bone development abnormal	17.24	15.38	4	31071	47	79713266
Lipase increased	16.80	15.38	26	31049	16440	79696873
Balance disorder	16.45	15.38	9	31066	98848	79614465
Rhabdomyolysis	16.29	15.38	10	31065	103121	79610192
Cardiac tamponade	16.15	15.38	19	31056	9257	79704056
Impaired healing	16.07	15.38	7	31068	87648	79625665
Neoplasm malignant	15.87	15.38	37	31038	31773	79681540
Suicidal ideation	15.84	15.38	5	31070	76335	79636978
Fibromyalgia	15.71	15.38	3	31072	64337	79648976
Decreased appetite	15.69	15.38	203	30872	342215	79371098
Ventricular enlargement	15.69	15.38	7	31068	725	79712588
Drug reaction with eosinophilia and systemic symptoms	15.68	15.38	3	31072	64241	79649072
Cytogenetic abnormality	15.67	15.38	8	31067	1117	79712196
White blood cell count increased	15.58	15.38	64	31011	74569	79638744
Tumour lysis syndrome	15.56	15.38	31	31044	23908	79689405

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01EA02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS BCR-ABL tyrosine kinase inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D047428	Protein Kinase Inhibitors
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:38637	tyrosine kinase inhibitors
CHEBI has role	CHEBI:149553	anticoronaviral drug

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Blastic phase chronic myeloid leukemia	indication	413656006
Chronic phase chronic myeloid leukemia	indication	413847001
Philadelphia chromosome-positive acute lymphoblastic leukemia	indication	425688002
Philadelphia Chromosome Positive Chronic Myelocytic Leukemia	indication
Chronic Myelocytic Leukemia Accelerated Phase	indication
Acute hemorrhage	contraindication	8573003
Myocardial infarction	contraindication	22298006	DOID:5844
Torsades de pointes	contraindication	31722008
Body fluid retention	contraindication	43498006
Chronic heart failure	contraindication	48447003
Gastrointestinal hemorrhage	contraindication	74474003
Left heart failure	contraindication	85232009
Prolonged QT interval	contraindication	111975006
Disease of liver	contraindication	235856003	DOID:409
Edema	contraindication	267038008
Anemia	contraindication	271737000	DOID:2355
Cerebral hemorrhage	contraindication	274100004
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Pericardial effusion	contraindication	373945007	DOID:118
Ascites	contraindication	389026000
Breastfeeding (mother)	contraindication	413712001
Congenital long QT syndrome	contraindication	442917000
Pleural Effusions	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.56	acidic
pKa2	7.72	Basic
pKa3	4.89	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
100MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	May 30, 2008	RX	TABLET	ORAL	Nov. 9, 2024	TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
140MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	Oct. 28, 2010	RX	TABLET	ORAL	Nov. 9, 2024	TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
20MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	June 28, 2006	RX	TABLET	ORAL	Nov. 9, 2024	TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
50MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	June 28, 2006	RX	TABLET	ORAL	Nov. 9, 2024	TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
70MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	June 28, 2006	RX	TABLET	ORAL	Nov. 9, 2024	TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
80MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	Oct. 28, 2010	RX	TABLET	ORAL	Nov. 9, 2024	TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
100MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	May 30, 2008	RX	TABLET	ORAL	May 9, 2025	PEDIATRIC EXCLUSIVITY
140MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	Oct. 28, 2010	RX	TABLET	ORAL	May 9, 2025	PEDIATRIC EXCLUSIVITY
20MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	June 28, 2006	RX	TABLET	ORAL	May 9, 2025	PEDIATRIC EXCLUSIVITY
50MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	June 28, 2006	RX	TABLET	ORAL	May 9, 2025	PEDIATRIC EXCLUSIVITY
70MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	June 28, 2006	RX	TABLET	ORAL	May 9, 2025	PEDIATRIC EXCLUSIVITY
80MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	Oct. 28, 2010	RX	TABLET	ORAL	May 9, 2025	PEDIATRIC EXCLUSIVITY
100MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	May 30, 2008	RX	TABLET	ORAL	Dec. 21, 2025	INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
140MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	Oct. 28, 2010	RX	TABLET	ORAL	Dec. 21, 2025	INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
20MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	June 28, 2006	RX	TABLET	ORAL	Dec. 21, 2025	INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
50MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	June 28, 2006	RX	TABLET	ORAL	Dec. 21, 2025	INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
70MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	June 28, 2006	RX	TABLET	ORAL	Dec. 21, 2025	INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
80MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	Oct. 28, 2010	RX	TABLET	ORAL	Dec. 21, 2025	INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
100MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	May 30, 2008	RX	TABLET	ORAL	June 21, 2026	PEDIATRIC EXCLUSIVITY
140MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	Oct. 28, 2010	RX	TABLET	ORAL	June 21, 2026	PEDIATRIC EXCLUSIVITY
20MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	June 28, 2006	RX	TABLET	ORAL	June 21, 2026	PEDIATRIC EXCLUSIVITY
50MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	June 28, 2006	RX	TABLET	ORAL	June 21, 2026	PEDIATRIC EXCLUSIVITY
70MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	June 28, 2006	RX	TABLET	ORAL	June 21, 2026	PEDIATRIC EXCLUSIVITY
80MG	SPRYCEL	BRISTOL MYERS SQUIBB	N021986	Oct. 28, 2010	RX	TABLET	ORAL	June 21, 2026	PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Mast/stem cell growth factor receptor Kit	Kinase	P10721	KIT_HUMAN	INHIBITOR	Kd	9.24	CHEMBL	CHEMBL
Proto-oncogene tyrosine-protein kinase Src	Kinase	P12931	SRC_HUMAN	INHIBITOR	Kd	9.68	CHEMBL	CHEMBL
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN	INHIBITOR	Kd	9.70	CHEMBL	CHEMBL
Tyrosine-protein kinase Yes	Kinase	P07947	YES_HUMAN	INHIBITOR	Kd	9.52	CHEMBL	CHEMBL
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN	INHIBITOR	Kd	9.10	CHEMBL	CHEMBL
Ephrin type-A receptor 2	Kinase	P29317	EPHA2_HUMAN	INHIBITOR	Kd	9.07	CHEMBL	CHEMBL
Platelet-derived growth factor receptor beta	Kinase	P09619	PGFRB_HUMAN	INHIBITOR	Kd	9.20	CHEMBL	CHEMBL
Tyrosine-protein kinase ABL1	Kinase	P00519	ABL1_HUMAN	INHIBITOR	IC50	9.60	IUPHAR	CHEMBL
Serine/threonine-protein kinase B-raf	Kinase	P15056	BRAF_HUMAN		Kd	6.30	CHEMBL
Receptor-type tyrosine-protein kinase FLT3	Kinase	P36888	FLT3_HUMAN		Kd	5.49	CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret	Kinase	P07949	RET_HUMAN		Kd	6.41	CHEMBL
Vascular endothelial growth factor receptor 1	Kinase	P17948	VGFR1_HUMAN		Kd	5.30	CHEMBL
Vascular endothelial growth factor receptor 2	Kinase	P35968	VGFR2_HUMAN		Kd	5.54	CHEMBL
Macrophage colony-stimulating factor 1 receptor	Kinase	P07333	CSF1R_HUMAN		Kd	9.24	CHEMBL
Platelet-derived growth factor receptor alpha	Kinase	P16234	PGFRA_HUMAN		Kd	9.33	CHEMBL
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN		Kd	5.85	CHEMBL
Myosin light chain kinase, smooth muscle	Kinase	Q15746	MYLK_HUMAN		Kd	7.14	CHEMBL
Fibroblast growth factor receptor 3	Kinase	P22607	FGFR3_HUMAN		Kd	5.41	CHEMBL
Tyrosine-protein kinase HCK	Kinase	P08631	HCK_HUMAN	INHIBITOR	Kd	9.46	CHEMBL
Receptor tyrosine-protein kinase erbB-4	Kinase	Q15303	ERBB4_HUMAN		Kd	7.26	CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Kinase	O00329	PK3CD_HUMAN		IC50	4.52	CHEMBL
cAMP-dependent protein kinase catalytic subunit beta	Kinase	P22694	KAPCB_HUMAN		Kd	5.92	CHEMBL
Tyrosine-protein kinase JAK2	Kinase	O60674	JAK2_HUMAN		Kd	6	CHEMBL
Tyrosine-protein kinase SYK	Kinase	P43405	KSYK_HUMAN		Kd	5.54	CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle	Kinase	Q9H1R3	MYLK2_HUMAN		Kd	5.46	CHEMBL
Tyrosine-protein kinase CSK	Kinase	P41240	CSK_HUMAN		Kd	9	CHEMBL
Ephrin type-A receptor 8	Kinase	P29322	EPHA8_HUMAN		Kd	9.62	CHEMBL
Tyrosine-protein kinase Lyn	Kinase	P07948	LYN_HUMAN	INHIBITOR	Kd	9.24	CHEMBL
Cytoplasmic tyrosine-protein kinase BMX	Kinase	P51813	BMX_HUMAN		Kd	8.85	CHEMBL
Serine/threonine-protein kinase Nek2	Kinase	P51955	NEK2_HUMAN		Kd	5.19	CHEMBL
LIM domain kinase 1	Kinase	P53667	LIMK1_HUMAN		Kd	6.24	CHEMBL
Fibroblast growth factor receptor 1	Kinase	P11362	FGFR1_HUMAN		Kd	5.43	CHEMBL
Serine/threonine-protein kinase 10	Kinase	O94804	STK10_HUMAN		Kd	5.92	CHEMBL
Abelson tyrosine-protein kinase 2	Kinase	P42684	ABL2_HUMAN		Kd	9.77	CHEMBL
Mitogen-activated protein kinase 11	Kinase	Q15759	MK11_HUMAN		Kd	6.39	CHEMBL
Ephrin type-A receptor 5	Kinase	P54756	EPHA5_HUMAN		Kd	9.62	CHEMBL
Ephrin type-A receptor 4	Kinase	P54764	EPHA4_HUMAN		Kd	8.92	CHEMBL
Fibroblast growth factor receptor 2	Kinase	P21802	FGFR2_HUMAN		Kd	5.85	CHEMBL
Serine/threonine-protein kinase N1	Kinase	Q16512	PKN1_HUMAN		Kd	6.45	CHEMBL
Protein kinase C theta type	Kinase	Q04759	KPCT_HUMAN		Kd	6.15	CHEMBL
Ephrin type-A receptor 6	Kinase	Q9UF33	EPHA6_HUMAN		Kd	5.68	CHEMBL
TRAF2 and NCK-interacting protein kinase	Kinase	Q9UKE5	TNIK_HUMAN		Kd	5.70	CHEMBL
Casein kinase I isoform epsilon	Kinase	P49674	KC1E_HUMAN		Kd	5.82	CHEMBL
Tyrosine-protein kinase Fgr	Kinase	P09769	FGR_HUMAN	INHIBITOR	Kd	9.30	CHEMBL
Aurora kinase A	Kinase	O14965	AURKA_HUMAN		Kd	5.03	CHEMBL
Serine/threonine-protein kinase 36	Kinase	Q9NRP7	STK36_HUMAN		Kd	6.68	CHEMBL
Ephrin type-A receptor 3	Kinase	P29320	EPHA3_HUMAN		Kd	10.03	CHEMBL
Mitogen-activated protein kinase 14	Kinase	Q16539	MK14_HUMAN		Kd	7.57	CHEMBL
Tyrosine-protein kinase FRK	Kinase	P42685	FRK_HUMAN	INHIBITOR	Kd	9.51	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5	Kinase	Q9Y4K4	M4K5_HUMAN		Kd	7.35	CHEMBL
Mitogen-activated protein kinase kinase kinase 4	Kinase	Q9Y6R4	M3K4_HUMAN		Kd	6.51	CHEMBL
Cyclin-G-associated kinase	Kinase	O14976	GAK_HUMAN		Kd	8.59	CHEMBL
Receptor-interacting serine/threonine-protein kinase 2	Kinase	O43353	RIPK2_HUMAN		Kd	7.51	CHEMBL
Ephrin type-B receptor 1	Kinase	P54762	EPHB1_HUMAN		Kd	9.35	CHEMBL
Serine/threonine-protein kinase 4	Kinase	Q13043	STK4_HUMAN		Kd	5.42	CHEMBL
Activated CDC42 kinase 1	Kinase	Q07912	ACK1_HUMAN		Kd	8.25	CHEMBL
STE20-like serine/threonine-protein kinase	Kinase	Q9H2G2	SLK_HUMAN		Kd	6.14	CHEMBL
Epithelial discoidin domain-containing receptor 1	Kinase	Q08345	DDR1_HUMAN		Kd	9.16	CHEMBL
Ephrin type-B receptor 4	Kinase	P54760	EPHB4_HUMAN		Kd	9.47	CHEMBL
Activin receptor type-1B	Kinase	P36896	ACV1B_HUMAN		Kd	6.48	CHEMBL
Serine/threonine-protein kinase receptor R3	Kinase	P37023	ACVL1_HUMAN		Kd	6.34	CHEMBL
Activin receptor type-1	Kinase	Q04771	ACVR1_HUMAN		Kd	6.21	CHEMBL
TGF-beta receptor type-2	Kinase	P37173	TGFR2_HUMAN		Kd	5.54	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1	Kinase	Q02750	MP2K1_HUMAN		Kd	6	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2	Kinase	P36507	MP2K2_HUMAN		Kd	5.85	CHEMBL
Tyrosine-protein kinase ITK/TSK	Kinase	Q08881	ITK_HUMAN		IC50	6.64	CHEMBL
Protein-tyrosine kinase 6	Kinase	Q13882	PTK6_HUMAN		Kd	8.11	CHEMBL
MAP kinase-activated protein kinase 2	Kinase	P49137	MAPK2_HUMAN		Kd	6.27	CHEMBL
Tyrosine-protein kinase BTK	Kinase	Q06187	BTK_HUMAN		Kd	8.85	CHEMBL
Tyrosine-protein kinase Tec	Kinase	P42680	TEC_HUMAN		Kd	7.89	CHEMBL
Ephrin type-B receptor 2	Kinase	P29323	EPHB2_HUMAN		Kd	9.41	CHEMBL
Non-receptor tyrosine-protein kinase TNK1	Kinase	Q13470	TNK1_HUMAN		Kd	6.17	CHEMBL
Non-receptor tyrosine-protein kinase TYK2	Kinase	P29597	TYK2_HUMAN		Kd	6.96	CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Kinase	P42336	PK3CA_HUMAN		IC50	4.42	CHEMBL
Wee1-like protein kinase	Kinase	P30291	WEE1_HUMAN		Kd	5.15	CHEMBL
Serine/threonine-protein kinase 25	Kinase	O00506	STK25_HUMAN		Kd	5.47	CHEMBL
Mitogen-activated protein kinase kinase kinase MLT	Kinase	Q9NYL2	MLTK_HUMAN		Kd	7.35	CHEMBL
Tyrosine-protein kinase TXK	Kinase	P42681	TXK_HUMAN		Kd	8.68	CHEMBL
LIM domain kinase 2	Kinase	P53671	LIMK2_HUMAN		Kd	7.07	CHEMBL
Serine/threonine-protein kinase 26	Kinase	Q9P289	STK26_HUMAN		Kd	5.72	CHEMBL
Serine/threonine-protein kinase NLK	Kinase	Q9UBE8	NLK_HUMAN		Kd	6.59	CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 4	Kinase	Q9P2K8	E2AK4_HUMAN		Kd	5.80	CHEMBL
Serine/threonine-protein kinase SIK2	Kinase	Q9H0K1	SIK2_HUMAN		Kd	8.19	CHEMBL
Activin receptor type-2A	Kinase	P27037	AVR2A_HUMAN		Kd	6.68	CHEMBL
Activin receptor type-2B	Kinase	Q13705	AVR2B_HUMAN		Kd	6.24	CHEMBL
Serine/threonine-protein kinase TNNI3K	Kinase	Q59H18	TNI3K_HUMAN		Kd	7.96	CHEMBL
Discoidin domain-containing receptor 2	Kinase	Q16832	DDR2_HUMAN		Kd	8.52	CHEMBL
Myotonin-protein kinase	Kinase	Q09013	DMPK_HUMAN		Kd	5.89	CHEMBL
Chaperone activity of bc1 complex-like, mitochondrial	Kinase	Q8NI60	COQ8A_HUMAN		Kd	6.72	CHEMBL
Serine/threonine-protein kinase MRCK gamma	Kinase	Q6DT37	MRCKG_HUMAN		Kd	5.92	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1	Kinase	Q92918	M4K1_HUMAN		Kd	6.01	CHEMBL
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Kinase	Q99640	PMYT1_HUMAN		Kd	6.89	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3	Kinase	Q8IVH8	M4K3_HUMAN		Kd	6.19	CHEMBL
Aurora kinase B	Kinase	Q96GD4	AURKB_HUMAN		IC50	5.19	CHEMBL
Tyrosine-protein kinase Blk	Kinase	P51451	BLK_HUMAN	INHIBITOR	Kd	9.68	CHEMBL
Bone morphogenetic protein receptor type-1A	Kinase	P36894	BMR1A_HUMAN		Kd	5.15	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4	Kinase	O95819	M4K4_HUMAN		Kd	5.51	CHEMBL
Serine/threonine-protein kinase MRCK alpha	Kinase	Q5VT25	MRCKA_HUMAN		Kd	5.70	CHEMBL
Serine/threonine-protein kinase MRCK beta	Kinase	Q9Y5S2	MRCKB_HUMAN		Kd	5.68	CHEMBL
Serine/threonine-protein kinase PAK 4	Kinase	O96013	PAK4_HUMAN		Kd	6.13	CHEMBL
Serine/threonine-protein kinase SIK1	Kinase	P57059	SIK1_HUMAN		Kd	8.41	CHEMBL
Tyrosine-protein kinase Srms	Kinase	Q9H3Y6	SRMS_HUMAN	INHIBITOR	Kd	7.89	CHEMBL
Dual specificity testis-specific protein kinase 1	Kinase	Q15569	TESK1_HUMAN		Kd	7.48	CHEMBL
TGF-beta receptor type-1	Kinase	P36897	TGFR1_HUMAN		Kd	6.64	CHEMBL
Ephrin type-A receptor 1	Kinase	P21709	EPHA1_HUMAN		Kd	8.39	CHEMBL
Ephrin type-B receptor 3	Kinase	P54753	EPHB3_HUMAN		Kd	8.16	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2	Kinase	Q12851	M4K2_HUMAN		Kd	5.89	CHEMBL
Misshapen-like kinase 1	Kinase	Q8N4C8	MINK1_HUMAN		Kd	6.37	CHEMBL
Ephrin type-B receptor 6	Kinase	O15197	EPHB6_HUMAN		Kd	10.41	CHEMBL
Mitogen-activated protein kinase kinase kinase 13	Kinase	O43283	M3K13_HUMAN		Kd	5.28	CHEMBL
Mitogen-activated protein kinase kinase kinase 2	Kinase	Q9Y2U5	M3K2_HUMAN		Kd	6.85	CHEMBL
Mitogen-activated protein kinase kinase kinase 3	Kinase	Q99759	M3K3_HUMAN		Kd	6.55	CHEMBL
Mitogen-activated protein kinase kinase kinase 7	Kinase	O43318	M3K7_HUMAN		Kd	5.43	CHEMBL
Serine/threonine-protein kinase TAO3	Kinase	Q9H2K8	TAOK3_HUMAN		Kd	5.64	CHEMBL
Serine/threonine-protein kinase ULK3	Kinase	Q6PHR2	ULK3_HUMAN		Kd	5.34	CHEMBL
Mitogen-activated protein kinase kinase kinase 19	Kinase	Q56UN5	M3K19_HUMAN		Kd	7.10	CHEMBL
Serine/threonine-protein kinase 35	Kinase	Q8TDR2	STK35_HUMAN		Kd	6.11	CHEMBL
Receptor tyrosine-protein kinase erbB-3	Kinase	P21860	ERBB3_HUMAN		Kd	7.74	CHEMBL
Mitogen-activated protein kinase kinase kinase 1	Kinase	Q13233	M3K1_HUMAN		Kd	5.90	CHEMBL
Serine/threonine-protein kinase SIK3	Kinase	Q9Y2K2	SIK3_HUMAN		Kd	7.55	CHEMBL
Wee1-like protein kinase 2	Kinase	P0C1S8	WEE2_HUMAN		Kd	6.70	CHEMBL
Bone morphogenetic protein receptor type-1B	Kinase	O00238	BMR1B_HUMAN		Kd	7.28	CHEMBL
Serine/threonine-protein kinase SBK1	Kinase	Q52WX2	SBK1_HUMAN		Kd	5.92	CHEMBL
Serine/threonine-protein kinase VRK2	Kinase	Q86Y07	VRK2_HUMAN		Kd	5.49	CHEMBL
Serine/threonine-protein kinase TAO2	Kinase	Q9UL54	TAOK2_HUMAN		Kd	5.27	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5	Kinase	Q13163	MP2K5_HUMAN		Kd	8.48	CHEMBL
Serine/threonine-protein kinase Nek11	Kinase	Q8NG66	NEK11_HUMAN		Kd	6.33	CHEMBL
MAP kinase p38	Kinase	O15264 P53778 Q15759 Q16539	MK13_HUMAN MK12_HUMAN MK11_HUMAN MK14_HUMAN		IC50	7	CHEMBL
Dual specificity mitogen-activated protein kinase kinase; MEK1/2	Kinase	P36507 Q02750	MP2K2_HUMAN MP2K1_HUMAN		IC50	5.77	CHEMBL
Bcr/Abl fusion protein	Kinase	P00519 P11274	ABL1_HUMAN BCR_HUMAN		IC50	9.10	CHEMBL
Tyrosine-protein kinase JAK3	Kinase	P52333	JAK3_HUMAN		Kd	6.19	CHEMBL
Myelin transcription factor 1	Transcription factor	Q01538	MYT1_HUMAN		IC50	7.20	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	4.84	CHEMBL
Transthyretin	Secreted	P02766	TTHY_HUMAN		Kd	5.51	CHEMBL
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	5.70	CHEMBL
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		Kd	7.10	CHEMBL
Serine/threonine-protein kinase mTOR	Kinase	P42345	MTOR_HUMAN		IC50	4.46	CHEMBL
Breakpoint cluster region protein	Kinase	P11274	BCR_HUMAN		Kd	8.30	CHEMBL
RAF proto-oncogene serine/threonine-protein kinase	Kinase	P04049	RAF1_HUMAN		Kd	6.24	CHEMBL
Proto-oncogene tyrosine-protein kinase LCK	Kinase		LCK_MOUSE		Ki	10.19	CHEMBL
Proto-oncogene tyrosine-protein kinase Src	Kinase		SRC_CHICK		Kd	7.96	CHEMBL
Tubulin alpha-1A chain	Structural		TBA1A_RAT		Kd	7.26	CHEMBL
Tyrosine-protein kinase Blk	Kinase		BLK_MOUSE		IC50	8.10	CHEMBL
Quinolone resistance protein NorA	Transporter		NORA_STAAU		IC50	4.94	CHEMBL
Calcium-dependent protein kinase 1	Kinase		CDPK1_PLAF7		Kd	6.19	CHEMBL

External reference:

ID	Source
4025488	VUID
N0000179780	NUI
D03658	KEGG_DRUG
475342	RXNORM
4025488	VANDF
C1455147	UMLSCUI
CHEBI:70839	CHEBI
1N1	PDB_CHEM_ID
CHEMBL1421	ChEMBL_ID
D000069439	MESH_DESCRIPTOR_UI
DB01254	DRUGBANK_ID
5678	IUPHAR_LIGAND_ID
RBZ1571X5H	UNII
3062316	PUBCHEM_CID
21648	MMSL
83173	MMSL
d05831	MMSL
011616	NDDF
422756008	SNOMEDCT_US
423658008	SNOMEDCT_US
863127-77-9	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
SPRYCEL	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0524	TABLET	70 mg	ORAL	NDA	27 sections
SPRYCEL	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0524	TABLET	70 mg	ORAL	NDA	27 sections
SPRYCEL	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0524	TABLET	70 mg	ORAL	NDA	27 sections
SPRYCEL	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0527	TABLET	20 mg	ORAL	NDA	27 sections
SPRYCEL	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0527	TABLET	20 mg	ORAL	NDA	27 sections
SPRYCEL	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0527	TABLET	20 mg	ORAL	NDA	27 sections
SPRYCEL	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0528	TABLET	50 mg	ORAL	NDA	27 sections
SPRYCEL	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0528	TABLET	50 mg	ORAL	NDA	27 sections
SPRYCEL	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0528	TABLET	50 mg	ORAL	NDA	27 sections
SPRYCEL	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0852	TABLET	100 mg	ORAL	NDA	27 sections
SPRYCEL	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0852	TABLET	100 mg	ORAL	NDA	27 sections
SPRYCEL	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0852	TABLET	100 mg	ORAL	NDA	27 sections
SPRYCEL	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0855	TABLET	80 mg	ORAL	NDA	27 sections
SPRYCEL	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0855	TABLET	80 mg	ORAL	NDA	27 sections
SPRYCEL	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0855	TABLET	80 mg	ORAL	NDA	27 sections
SPRYCEL	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0857	TABLET	140 mg	ORAL	NDA	27 sections
SPRYCEL	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0857	TABLET	140 mg	ORAL	NDA	27 sections
SPRYCEL	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0857	TABLET	140 mg	ORAL	NDA	27 sections
SPRYCEL	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5759	TABLET	70 mg	ORAL	NDA	28 sections